New-onset Diabetes as a Harbinger of Pancreatic Cancer: Is Early Diagnosis Possible?

Dana K. Andersen; Suresh T. Chari; Eithne Costello; Tatjana Crnogorac-Jurcevic; Phil A. Hart; Anirban Maitra; Stephen J. Pandol

doi:10.1002/9781119570097.ch51

New-onset Diabetes as a Harbinger of Pancreatic Cancer: Is Early Diagnosis Possible?

Dana K. Andersen, Suresh T. Chari, Eithne Costello, Tatjana Crnogorac-Jurcevic, Phil A. Hart, Anirban Maitra, Stephen J. Pandol

Pathology, Anatomical

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

This chapter summarizes the clinical studies which have identified new-onset diabetes (NOD) as a harbinger of pancreatic ductal adenocarcinoma (PDAC). It describes the ongoing efforts to identify biomarkers of PDAC-diabetes mellitus (DM), and proposes strategies which will enable the identification of PDAC at an early stage of the disease. Because PDAC-DM is frequently of new onset, a possible hypothesis is that the NOD associated with PDAC is a paraneoplastic phenomenon caused by the tumor. One approach to recognizing the cohort of NOD patients who are at high risk of PDAC is to identify the type of DM which is caused by the tumor and which is distinct from other DM types. The most promising candidate biomarker for pancreatogenic diabetes is the islet hormone pancreatic polypeptide. Validating and implementing biomarkers for early PDAC detection into clinical practice is a mutual urgent goal for scientists and clinicians alike across the Atlantic.

Original language	English (US)
Title of host publication	Clinical Pancreatology for Practising Gastroenterologists and Surgeons
Subtitle of host publication	Second Edition
Publisher	wiley
Pages	409-417
Number of pages	9
ISBN (Electronic)	9781119570097
ISBN (Print)	9781119570073
DOIs	https://doi.org/10.1002/9781119570097.ch51
State	Published - Jan 1 2021

Keywords

islet hormone pancreatic polypeptide
new-onset diabetes
pancreatic ductal adenocarcinoma
PDAC-diabetes mellitus

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/9781119570097.ch51

Cite this

@inbook{51c993c163294e37a73bf68c18b09055,

title = "New-onset Diabetes as a Harbinger of Pancreatic Cancer: Is Early Diagnosis Possible?",

abstract = "This chapter summarizes the clinical studies which have identified new-onset diabetes (NOD) as a harbinger of pancreatic ductal adenocarcinoma (PDAC). It describes the ongoing efforts to identify biomarkers of PDAC-diabetes mellitus (DM), and proposes strategies which will enable the identification of PDAC at an early stage of the disease. Because PDAC-DM is frequently of new onset, a possible hypothesis is that the NOD associated with PDAC is a paraneoplastic phenomenon caused by the tumor. One approach to recognizing the cohort of NOD patients who are at high risk of PDAC is to identify the type of DM which is caused by the tumor and which is distinct from other DM types. The most promising candidate biomarker for pancreatogenic diabetes is the islet hormone pancreatic polypeptide. Validating and implementing biomarkers for early PDAC detection into clinical practice is a mutual urgent goal for scientists and clinicians alike across the Atlantic.",

keywords = "islet hormone pancreatic polypeptide, new-onset diabetes, pancreatic ductal adenocarcinoma, PDAC-diabetes mellitus",

author = "Andersen, {Dana K.} and Chari, {Suresh T.} and Eithne Costello and Tatjana Crnogorac-Jurcevic and Hart, {Phil A.} and Anirban Maitra and Pandol, {Stephen J.}",

note = "Publisher Copyright: {\textcopyright} 2021 John Wiley and Sons Ltd.",

year = "2021",

month = jan,

day = "1",

doi = "10.1002/9781119570097.ch51",

language = "English (US)",

isbn = "9781119570073",

pages = "409--417",

booktitle = "Clinical Pancreatology for Practising Gastroenterologists and Surgeons",

publisher = "wiley",

}

TY - CHAP

T1 - New-onset Diabetes as a Harbinger of Pancreatic Cancer

T2 - Is Early Diagnosis Possible?

AU - Andersen, Dana K.

AU - Chari, Suresh T.

AU - Costello, Eithne

AU - Crnogorac-Jurcevic, Tatjana

AU - Hart, Phil A.

AU - Maitra, Anirban

AU - Pandol, Stephen J.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - This chapter summarizes the clinical studies which have identified new-onset diabetes (NOD) as a harbinger of pancreatic ductal adenocarcinoma (PDAC). It describes the ongoing efforts to identify biomarkers of PDAC-diabetes mellitus (DM), and proposes strategies which will enable the identification of PDAC at an early stage of the disease. Because PDAC-DM is frequently of new onset, a possible hypothesis is that the NOD associated with PDAC is a paraneoplastic phenomenon caused by the tumor. One approach to recognizing the cohort of NOD patients who are at high risk of PDAC is to identify the type of DM which is caused by the tumor and which is distinct from other DM types. The most promising candidate biomarker for pancreatogenic diabetes is the islet hormone pancreatic polypeptide. Validating and implementing biomarkers for early PDAC detection into clinical practice is a mutual urgent goal for scientists and clinicians alike across the Atlantic.

AB - This chapter summarizes the clinical studies which have identified new-onset diabetes (NOD) as a harbinger of pancreatic ductal adenocarcinoma (PDAC). It describes the ongoing efforts to identify biomarkers of PDAC-diabetes mellitus (DM), and proposes strategies which will enable the identification of PDAC at an early stage of the disease. Because PDAC-DM is frequently of new onset, a possible hypothesis is that the NOD associated with PDAC is a paraneoplastic phenomenon caused by the tumor. One approach to recognizing the cohort of NOD patients who are at high risk of PDAC is to identify the type of DM which is caused by the tumor and which is distinct from other DM types. The most promising candidate biomarker for pancreatogenic diabetes is the islet hormone pancreatic polypeptide. Validating and implementing biomarkers for early PDAC detection into clinical practice is a mutual urgent goal for scientists and clinicians alike across the Atlantic.

KW - islet hormone pancreatic polypeptide

KW - new-onset diabetes

KW - pancreatic ductal adenocarcinoma

KW - PDAC-diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85115762868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115762868&partnerID=8YFLogxK

U2 - 10.1002/9781119570097.ch51

DO - 10.1002/9781119570097.ch51

M3 - Chapter

AN - SCOPUS:85115762868

SN - 9781119570073

SP - 409

EP - 417

BT - Clinical Pancreatology for Practising Gastroenterologists and Surgeons

PB - wiley

ER -

New-onset Diabetes as a Harbinger of Pancreatic Cancer: Is Early Diagnosis Possible?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this